We rank companies based on fund manager, research analyst and news sentiment
ANVS stock icon

Annovis Bio, Inc.
ANVS

$11.63
4.26%
 

About: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Employees: 6

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 7 analysts
0
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

555% more call options, than puts

Call options by funds: $3.1M | Put options by funds: $473K

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

113% more capital invested

Capital invested by funds: $10.6M [Q3] → $22.5M (+$12M) [Q4]

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

21% more funds holding

Funds holding: 29 [Q3] → 35 (+6) [Q4]

0.6% less ownership

Funds ownership: 12.34% [Q3] → 11.74% (-0.6%) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$9
23%
downside
Avg. target
$29
146%
upside
High target
$36
210%
upside

7 analyst ratings

positive
86%
neutral
14%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
158%upside
$30
Buy
Maintained
2 Apr 2024
HC Wainwright & Co.
Raghuram Selvaraju
158%upside
$30
Buy
Reiterated
21 Mar 2024
Brookline Capital
Tyler Bussian
23%downside
$9
Hold
Downgraded
28 Feb 2024
Canaccord Genuity
Sumant Kulkarni
210%upside
$36
Buy
Initiated
29 Dec 2023
HC Wainwright & Co.
Raghuram Selvaraju
158%upside
$30
Buy
Reiterated
28 Nov 2023

Financial journalist opinion

Based on 5 articles about ANVS published over the past 30 days